Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0004352 (
autism
)
32,579
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Dysfunction of cerebral cortex in
autism
is thought to involve alterations in inhibitory neurotransmission. Here, we screened, in prefrontal cortex (PFC) of 15 subjects diagnosed with
autism
and 15 matched controls the expression of 44 transcripts that are either preferentially expressed in gamma-aminobutyric acidergic interneurons of the mature cortex or important for the development of inhibitory circuitry. Significant alterations in the
autism
cohort included decreased expression (-45%) of
RPP25
(15q24.1), which is located within the
autism
susceptibility locus, 15q22-26.
RPP25
, which encodes the 25 kDa subunit of ribonuclease P involved in tRNA and pre-ribosomal RNA processing, was developmentally regulated in cerebral cortex with peak levels of expression during late fetal development (human) or around birth (mouse). In the PFC,
RPP25
chromatin showed high levels of histone H3-lysine 4 trimethylation, an epigenetic mark associated with transcriptional regulation. Unexpectedly, and in contrast to peripheral tissues, levels of
RPP25
protein remained undetectable in fetal and adult cerebral cortex. Taken together, these findings suggest a potential role for the
RPP25
gene transcript in the neurobiology of developmental brain disorders.
Autism
Res 2010 Aug
PMID:RPP25 is developmentally regulated in prefrontal cortex and expressed at decreased levels in autism spectrum disorder. 2063 21